Abstract 953: An anti-CD38 antibody drug conjugate for the treatment of diverse hematologic malignancies

Purpose: The CD38 cell surface antigen is expressed in diverse hematologic malignancies including multiple myeloma, acute promyelocytic leukemia (PML), B-cell non-Hodgkin lymphoma (NHL), B-cell acute lymphoblastic leukemia (ALL), B-cell chronic lymphocytic leukemia (B-CLL),and T-cell ALL. Here, we assessed the antitumor activity of novel extracellular drug conjugates composed of anti-CD38 monoclonal antibodies conjugated to various steroidal...